Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: portal vein tumour thrombus (PVTT)
I · Intervention 중재 / 시술
rusTACE with a mean interval of 42 days between treatments
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The short interval between treatments and ultraselective embolization of tumour-feeding arteries contributed to favourable outcomes. [ADVANCES IN KNOWLEDGE] RusTACE can be safely performed in HCC with PVTT and has a high local control rate.
[OBJECTIVES] To investigate the safety and long-term effectiveness of repeated ultraselective transarterial chemoembolization (rusTACE) using a 1.7-Fr-tip microcatheter in hepatocellular carcinoma (HC
- 추적기간 25.0 months
APA
Yamamoto A, Kageyama K, et al. (2025). Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus.. The British journal of radiology, 98(1172), 1290-1297. https://doi.org/10.1093/bjr/tqaf112
MLA
Yamamoto A, et al.. "Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus.." The British journal of radiology, vol. 98, no. 1172, 2025, pp. 1290-1297.
PMID
40419936 ↗
Abstract 한글 요약
[OBJECTIVES] To investigate the safety and long-term effectiveness of repeated ultraselective transarterial chemoembolization (rusTACE) using a 1.7-Fr-tip microcatheter in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombus (PVTT).
[METHODS] This retrospective analysis includes HCC patients with PVTT treated with rusTACE between May 2014 and July 2022. A 1.7-Fr-tip microcatheter was used to perform rusTACE for ultraselective embolization of the tumour-feeding artery. Treatment was repeated at least 2 times within 2 months. Treatment responses, survival rates, adverse event, liver function, and tumour-feeding arteries were assessed.
[RESULTS] Twenty patients underwent rusTACE with a mean interval of 42 days between treatments. RusTACE was well-tolerated. Median survival time was 26.1 months, with 1-, 2-, 3-, and 5-year survival rates of 85.0%, 61.0%, 40.9%, and 24.6%, respectively. Complete response (CR) of PVTT was achieved in 75%. Among these, 35% maintained CR of PVTT throughout follow-up (mean, 25.0 months). Univariate analysis showed prognostic factors included Child-Pugh score 5, CR of PVTT, CR of systemic tumours at the end of rusTACE, and liver tumour burden <30%. In 17%, a peribiliary vascular plexus or communicating artery was identified as the tumour-feeding artery.
[CONCLUSIONS] RusTACE is a safe and effective treatment option for HCC with PVTT in selected patients (Child-Pugh class A). RusTACE showed a high CR rate and long overall survival. The short interval between treatments and ultraselective embolization of tumour-feeding arteries contributed to favourable outcomes.
[ADVANCES IN KNOWLEDGE] RusTACE can be safely performed in HCC with PVTT and has a high local control rate.
[METHODS] This retrospective analysis includes HCC patients with PVTT treated with rusTACE between May 2014 and July 2022. A 1.7-Fr-tip microcatheter was used to perform rusTACE for ultraselective embolization of the tumour-feeding artery. Treatment was repeated at least 2 times within 2 months. Treatment responses, survival rates, adverse event, liver function, and tumour-feeding arteries were assessed.
[RESULTS] Twenty patients underwent rusTACE with a mean interval of 42 days between treatments. RusTACE was well-tolerated. Median survival time was 26.1 months, with 1-, 2-, 3-, and 5-year survival rates of 85.0%, 61.0%, 40.9%, and 24.6%, respectively. Complete response (CR) of PVTT was achieved in 75%. Among these, 35% maintained CR of PVTT throughout follow-up (mean, 25.0 months). Univariate analysis showed prognostic factors included Child-Pugh score 5, CR of PVTT, CR of systemic tumours at the end of rusTACE, and liver tumour burden <30%. In 17%, a peribiliary vascular plexus or communicating artery was identified as the tumour-feeding artery.
[CONCLUSIONS] RusTACE is a safe and effective treatment option for HCC with PVTT in selected patients (Child-Pugh class A). RusTACE showed a high CR rate and long overall survival. The short interval between treatments and ultraselective embolization of tumour-feeding arteries contributed to favourable outcomes.
[ADVANCES IN KNOWLEDGE] RusTACE can be safely performed in HCC with PVTT and has a high local control rate.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy.
- Spatial Transcriptomics Analysis of Macrophage-to-Myofibroblast Transition in Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation.
- [A Case of MSI-H and Signet-Ring-Cell Carcinoma of the Colon].
- A Case of Anomalous Systemic Arterial Supply to the Posterior Basal Segment of Normal Lung in a Patient with Dextrocardia.
- [A Case of Signet Ring Cell Pancreatic Carcinoma Showing Long-Term Survival with Chemotherapy].
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.